Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Akouos, Inc.
  6. Summary
    AKUS   US00973J1016

AKOUOS, INC.

(AKUS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
10.27(c) 10.38(c) 10.36(c) 10.32(c) 10.01(c) Last
74 401 78 601 88 301 75 154 120 639 Volume
-1.53% +1.07% -0.19% -0.39% -3.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -82,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,20x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -96,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,80x
Yield 2022 -
Capitalization 345 M 345 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 69
Free-Float 96,5%
More Financials
Company
Akouos Inc. is a precision genetic medicine company. The Company is focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. The Company has developed a precision genetic medicine platform that incorporates a vector library consisting of variants of a small virus commonly used in gene therapy,... 
More about the company
Ratings of Akouos, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about AKOUOS, INC.
09/07AKOUOS : to Present at Upcoming September Virtual Investor Conferences
AQ
08/16AKOUOS : Files for Up to $300 Million Mixed-Securities Shelf
MT
08/12AKOUOS : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
08/12AKOUOS : Reports Second Quarter 2021 Financial Results and Provides Business Highlights (F..
PU
08/12AKOUOS, INC. : Results of Operations and Financial Condition, Financial Statements and Exh..
AQ
08/12AKOUOS : Reports Second Quarter 2021 Financial Results and Provides Business Highlights
AQ
08/12Akouos, Inc. Announces Earnings Results for the Second Quarter and Six Months Ended Jun..
CI
08/11AKOUOS' : Gene Therapy for Hearing Loss Gets Orphan Drug Designation in Europe
MT
08/11AKOUOS : Announces European Commission Designation of AK-OTOF for the Treatment of Otoferl..
AQ
08/04AKOUOS : to Present at Upcoming August Virtual Investor Conferences
AQ
06/25AKOUOS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/25AKOUOS, INC.(NASDAQGS : AKUS) dropped from Russell 2000 Growth Index
CI
06/25AKOUOS, INC.(NASDAQGS : AKUS) dropped from Russell 3000 Growth Index
CI
06/25AKOUOS, INC.(NASDAQGS : AKUS) dropped from Russell 2500 Growth Index
CI
06/25AKOUOS, INC.(NASDAQGS : AKUS) added to Russell Microcap Index
CI
More news
News in other languages on AKOUOS, INC.

- No features available -

More news
Analyst Recommendations on AKOUOS, INC.
More recommendations
Chart AKOUOS, INC.
Duration : Period :
Akouos, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKOUOS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 10,01 $
Average target price 30,00 $
Spread / Average Target 200%
EPS Revisions
Managers and Directors
Emmanuel J. Simons President, Chief Executive Officer & Director
Sachiyo Minegishi Chief Financial Officer & Treasurer
Arthur O. Tzianabos Chairman
Michael J. McKenna Chief Medical Officer
Alan K. Smith Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
AKOUOS, INC.-49.52%345
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156